Summary: Using competitive allele-speciˆc oligonucleotide hybridization with immunochromatographic strip (CASSOH), we have developed a simpliˆed method for the detection of eight polymorphisms that are especially important in the identiˆcation of drug responders or non-responders and patients at increased risk of drug toxicity. The genotyping method is unambiguously determined by the presence or the absence of visible purple lines on the immunochromatographic strip, and results are obtained within 5 min after PCR. This method is rapid, highly sensitive, simpliˆed, and should be suitable for point-ofcare genotyping in clinical settings.
Introduction
Clinical application of pharmacogenetic information is important in customizing the species, optimal dosage, and schedule of drug for individual patients. Pharmacogenetics involves determining the genetic polymorphisms in‰uencing drug exposure levels. Speciˆcally, increased toxicity or altered e‹cacy can result from variations in a gene coding for an important drug metabolizing enzyme or phase I or II enzyme. Known alterations in genes in‰uencing the drug response include single nucleotide polymorphisms (SNPs) at loci for CYP2C19, 1, 2) N-acetyltransferase 2 (NAT2 ), [3] [4] [5] thiopurine S-methyltransferase (TPMT ), [6] [7] [8] [9] uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1 ), 10, 11) and mitochondrial DNA (mtDNA). 12) Prior to drug treatment, it is very desirable to use bedside genotyping methods to identify drug responders or non-responders as well as patients at increased risk of toxicity. Numerous SNP detection methods have been developed, including PCR-RFLP, allele-speciˆc PCR, 13) PCR-SSCP, 14) oligonucleotide ligation assay, 15) TaqMan PCR, [16] [17] [18] invader assay, 19, 20) pyrosequencing, 21) microarray, 22) and matrix-assisted laser desorption W ionisation-time of ‰ight mass spectrometry. 23) However these require expensive instrumentation and substantial technical expertise.
Matsubara and Kure 24) have recently developed the competitive allele-speciˆc short oligonucleotide hybridization (CASSOH) with immunochromatographic strip for the detection of some prevalent disease-causing mutations and clinically important polymorphisms. This is a rapid and simpliˆed method for SNP detection that demands neither technical expertise nor expensive instruments. In this report, we use this assay and either puriˆed DNA or unprocessed whole blood as templates to successfully detect SNPs CYP2C19 (CYP2C19 
Materials and Methods
Isolation of DNA from human blood: The local ethics committee of Tohoku Pharmaceutical University and Tohoku University Hospital approved the study, and all blood donors provided written, informed 24) with minor modiˆcations. The principle of the method is illustrated in Fig. 1 . A target sequence containing a SNP site is ampliˆed by PCR with a pair of PCR primers, one of which is labeled with digoxigenin (DIG) at its 5?-end. The PCR reaction mixture also contains two sets of hybridization probes. One set is used for the detection of the wild-type nucleotide sequence and consists of an oligonucleotide containing the wild-type sequence labeled with biotin (Bio) at its 3?-end and an unlabeled oligonucleotide containing the mutant sequence (reaction A). The second set consists of an oligonucleotide containing the mutant sequence labeled with Bio at its 3?-end and an unlabeled oligonucleotide containing the wild-type sequence (reaction B). All hybridization probes are designed on the strand opposite to a DIG-labeled PCR primer. A summary of the primers and probes used is presented in Table 1 .
The standard PCR was carried out in a reaction mixture containing 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl2, 250 mM each dNTP, 1 mM PCR forward primer, 1 mM PCR reverse primer, 600 nM biotinylated probe, 3 mM unlabeled competing probe, 1.25 U of Ex Taq DNA polymerase (TaKaRa, Otsu, Japan), and 0.04 to 100 ng of genomic DNA in a total volume of 20 mL. The PCR reactions were performed in a BIO-RAD iCycler (Hercules, CA, USA) with the following cycling conditions: denaturation at 949 C for 3 min, followed by 35 cycles of denaturation at 989 C for 10 sec, annealing at 559 C for 30 sec, and extension at 729 C for 30 sec, and,ˆnally, successive incubations of 729 C for 3 min, 989 C for 3 min, 659 C for 1 min, 559 C for 1 min, 459 C for 1 min, 359 C for 1 min, and 259 C for 1 min.
The direct PCR using whole blood as template was carried out in a PCR reaction mixture containing 4 mL of 5X Ampdirect-A (Shimadzu, Kyoto Japan), 4 mL of 5X Amp Addition-1 (Shimadzu, Kyoto Japan), 250 mM each dNTP, 1 mM PCR forward primer, 1 mM PCR reverse primer, 600 nM biotinylated probe, 3 mM unlabeled competing probe, 1.25 U of Ex Taq DNA polymerase (TaKaRa, Otsu, Japan), and 0.2 to 1 mL of blood in a total volume of 20 mL. Whole blood was obtained by scratching of theˆngertip with a needle. The PCR reactions were performed in the BIO-RAD iCycler with the following cycling conditions: denaturation at 949 C for 4.5 min, followed by 45 cycles of A 5 mL portion of the PCR reaction mixture is pipetted onto the sample application pad of a DNA detection test strip (Roche Diagnostics, Mannheim, Germany). The DNA test strip uses a nitrocellulose membrane with a line of immobilized streptavidin together with a conjugate pad impregnated with gold particle-conjugated anti-DIG mouse monoclonal antibody. The bottom end of the strip is immersed in chromatographic buŠer at room temperature for approximately 5 sec to initiate chromatography. As the buŠer and gold-labeled anti-DIG antibody contained in the test strip pad migrate through the sample, the conjugated antibody binds to the DNA-oligonucleotide hybrid. This complex is further trapped by immobilized streptavidin on the test strip, forming a visible purple line after 5 min. The genotype of the specimen is determined by the presence or absence of purple lines in reactions A and B.
Results and Discussion Figure 2 shows representative results for mtDNA (1555AÀG) (Fig. 2a) and NAT2 * 6 (590GÀA) (Fig. 2b) when puriˆed DNA was used as a template for the CASSOH assay. False positive or false negative signals were not observed. There was a 100z match in the genotyping results of the 1555A-homoplasmy and 1555G-homoplasmy of mtDNA and the 590G-homozygotes, heterozygotes, and 590A-homozygotes of NAT2. Figure 2c shows that, using the primers and probes listed in Table 1 . Although signal intensities between wild-type probes and mutant probes in each heterozygous samples of CYP2C19*3, NAT2*5, NAT2*7, TPMT*3C and UGT1A1*27 were slightly diŠerent, no false-negative signals were observed under the conditions. To estimate the precision and reproducibility of the assay, selected samples (n＝3 each) with a known genotype were analyzed in duplicate. All samples were tested for genotypes by sequencing and by CASSOH assay, and identical results were obtained by the two methods (data not shown). The detection limit of this assay was approximately 0.04 ng of template DNA. Test results on the dried DNA detection test strips were stable for at least 3 years at room temperature (data not shown).
SNP genotyping can generally be divided into two steps: puriˆcation of DNA from blood and allele detection. The DNA puriˆcation step is required because DNA polymerases are susceptible to inhibition by endogenous substances, including haemoglobin and bile acids. Puriˆcation of DNA is often labor-intensive, time-consuming, and costly, and it enhances the risk of back-or cross-contamination of samples. In the present study, we tested whether Ampdirect-A and Amp Addition-1, a reagent cocktail that suppresses the inhibitors in blood, is useful on CASSOH assay. Figure 2d shows representative results for mtDNA (1555AÀG) when whole blood was used as a template for the CASSOH assay. We found that all SNPs tested in this study could be detected by the CASSOH assay in the presence of this cocktail without prior extraction of the DNA (data not shown). In contrast, an ampliˆed band was not produced by PCR when a blood sample was used in the absence of this reagent cocktail. Typically, a 1 mL sample of whole blood yielded 15 to 60 ng of DNA, and the detection limit for this assay in the presence of Ampdirect was approximately 0.2 mL whole blood (3 to 12 ng of DNA). The entire assay can be completed in less than 3 h, and costs approximately $7 per sample. Thus, the CASSOH assay for SNP determination avoids the need for sample puriˆcation, leading to a considerable savings in time, cost, and eŠort.
In summary, we have developed a CASSOH-based genotyping method using whole blood as a template for eight polymorphisms that are especially important in the Japanese population for identiˆcation of drug responders or non-responders and patients at increased risk of drug toxicity. This method is rapid, highly sensitive, simple, and should be suitable for routine clinical genotyping. 
